🔎 Trials Near Me

Beranda › Leukemia Mieloid Akut › Colorado › Denver

Uji klinis Leukemia Mieloid Akut di Denver, CO

12 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Denver (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • AdventHealth Porter, Denver
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Menerima pesertaFase 3
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
6 Months – 21 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Menerima pesertaFase 3
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07022678

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

Menerima pesertaFase 1
  • Colorado Blood Cancer Institute, Denver
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06834282

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Menerima pesertaFase 1/2
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Menerima pesertaFase 3
  • Colorado Blood Cancer Institute, Denver
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Menerima pesertaFase 1
  • Colorado Blood Cancer Institute, Denver
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Menerima pesertaStudi observasional
  • Presbyterian St. Luke's/Colorado Blood Cancer Institute, Denver
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Menerima pesertaFase 1/2
  • Colorado Blood Cancer Institute, Denver
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 24 Mar 2026 · NCT04988555

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Menerima pesertaFase 1
  • Colorado Blood Cancer Institute, Denver
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT05735184

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Menerima pesertaSukarelawan sehat diterima
  • University of Colorado Denver I Anschutz Medical Campus, Denver
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 25 Jul 2025 · NCT05237258

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Menerima pesertaFase 1
  • Colorado Blood Cancer Institute, Denver
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Mei 2025 · NCT06634394

Uji klinis Leukemia Mieloid Akut di kota lain

Studi lain di Denver

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.